Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Skin Neoplasms × oblimersen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 5 Lymphoma, Large B-Cell, Diffuse 5 Rectal Neoplasms 3 Lymphoma, Follicular 3 Lung Neoplasms 3 Leukemia 3 Colorectal Neoplasms 3 Colonic Neoplasms 3 Waldenstrom Macroglobulinemia 2 Small Cell Lung Carcinoma 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms, Plasma Cell 2 Multiple Myeloma 2 Lymphoma, Mantle-Cell 2 Leukemia, Myeloid, Acute 2 Leukemia, Lymphocytic, Chronic, B-Cell 2 Esophageal Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Wilms Tumor 1 Uveal Melanoma 1 Urinary Bladder Neoplasms 1 Unspecified Adult Solid Tumor, Protocol Specific 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Skin Neoplasms 1 Ovarian Neoplasms 1

Interventions

pembrolizumab 20 Nivolumab 20 aldesleukin 19 Cyclophosphamide 18 Ipilimumab 16 fludarabine 14 Interleukin-2 14 fludarabine phosphate 12 cemiplimab 11 Radiotherapy 7 Biopsy 7 dabrafenib 6 Surveys and Questionnaires 6 Fluorouracil 6 Dacarbazine 6 trametinib 5 Vemurafenib 5 Radiation 5 Blood Specimen Collection 5 Aminolevulinic Acid 5 binimetinib 4 Temozolomide 4 Surgical Procedures, Operative 4 Sirolimus 4 Educational Status 4 sonidegib 3 montanide ISA 51 3 encorafenib 3 avelumab 3 Sodium Chloride 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00518895 2011-11-07

AGENDA

Genta Incorporated

Phase 3 Completed

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡